SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 32846.
  • 2
    Van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight–week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44: 151524.
  • 3
    Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review [review]. Rheumatology (Oxford) 2004; 43: 26771.
  • 4
    Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 83341.
  • 5
    Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials. J Rheumatol 1998; 25: 3643.
  • 6
    Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 65565.
  • 7
    Strand V, Morgan SL, Baggott JE, Alarcon GS. Folic acid supplementation and methotrexate efficacy: comment on articles by Schiff, Emery et al, and others [letter]. Arthritis Rheum 2000; 43: 26156.
  • 8
    Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al, and the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 254250.
  • 9
    Schiff MH. Leflunomide versus methotrexate: a comparison of the European and American experience. Scand J Rheumatol Suppl 1999; 112: 315.
  • 10
    Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 4155.
  • 11
    Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79: 51624.
  • 12
    Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I, on behalf of the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000; 43: 495505.
  • 13
    Becker SO, Ichino A. Estimation of average treatment effects based on propensity scores. Stata J 2002; 2: 35877.
  • 14
    Furst DE, Cohen S, Emery P, Dorrier K, Simpson K. Does folic acid (FA) decrease the efficacy as well as the toxicity of methotrexate (MTX) in rheumatoid arthritis (RA)? [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S373.